Our science
Twenty years of research. One bacterium. A new understanding of metabolic health.
Everything we make begins with Akkermansia muciniphila, discovered by our scientists in the mucus layer of the human gut, and the two decades of work it took to turn
that discovery into a supplement.
Our team
The people behind the science.
Behind every METAbiotics product is a team of pioneering scientists, clinicians, and biotechnology experts who have dedicated decades to understanding, developing, and producing Akkermansia muciniphila MucT®. From the original discovery of Akkermansia to clinical research and manufacturing excellence, their shared commitment ensures that every product is grounded in rigorous science and uncompromising quality.
Pr. Willem de Vos
Chair of Microbiology, Wageningen University, Professor Emeritus, University of Helsinki, Founder of The Akkermansia Company
"When we first identified Akkermansia muciniphila in the human gut, we could not have predicted the impact it would have on metabolic health research. More than two decades later, the science continues to confirm its importance for gut barrier integrity and metabolic function."
Anneleen Segers, PhD
Head of lab and medical affairs, The Akkermansia Company
"Scientific credibility is built through reproducible research, rigorous clinical investigation, and continuous questioning. The expanding evidence behind Akkermansia muciniphila MucT® reflects decades of work dedicated to understanding its role in human metabolic health"
Bart Smit, PhD
Head of Fermentation and Production, The Akkermansia Company
"My role is to translate breakthrough microbiome science from the laboratory into sustainable fermentation processes at industrial scale. From stainless steel fermenters to the final ingredient, the process has been optimized to ensure the highest quality of Akkermansia MucT® cells."
Where it started
Wageningen University, the Netherlands.
In the early 2000s, our microbiologists at Wageningen were studying the mucus layer of the human gut, a thin, living barrier most of medicine had overlooked. What they found there had never been described before: a bacterium making its home in the mucus itself, quietly shaping human metabolism. They named it Akkermansia muciniphila. And for the next twenty years, they kept working.
The mechanism
It doesn't add to your gut. It strengthens what's already there.
Most probiotics introduce new bacteria and hope they take. Akkermansia works differently. It lives in the mucus layer that lines your gut, the barrier that decides what enters your bloodstream and what doesn't. When that barrier is intact, metabolism runs the way it's supposed to. When it's compromised, the effects show up everywhere: weight, glucose, energy, inflammation.
For years, the field assumed live bacteria were the only kind that mattered. Our team ran the trials that changed that. Through a proprietary pasteurization process, we developed Akkermansia MucT®, a stable, non-live form that survives stomach acid and bile and delivers its bioactive components exactly where they work. And in head-to-head human trials, pasteurized Akkermansia consistently outperformed live.
The evidence
The most clinically studied Akkermansia in humans.
Every claim we make is grounded in peer-reviewed human research.
-
Improvements in insulin sensitivity and inflammatory markers over 12 weeks*
Read moreMetabolic Health
Pasteurized Akkermansia MucT® supported improvements in insulin sensitivity and inflammatory markers over 12 weeks in overweight and obese adults.*
-
Supported markers of Gut Barrier Function
Read moreGut Microbiome
The microbes in our gut microbiome have a large impact on our overall health and immunity. -
Supports Weight Loss Maintenance*
Read moreWeight Maintenance
New clinical results show pasteurized Akkermansia MucT® supports weight loss maintenance following an initial reduction period.*
-
Well tolerated across long-term supplementation
Read moreThe Science behind Akkermansia
Multiple studies confirm Akkermansia MucT® is well tolerated across long-term supplementation in healthy adults.*
Recognized by the standards that matter
The only Akkermansia authorized by EFSA.
In 2021, Akkermansia MucT® became the first pasteurized bacterium to receive Novel Food authorization from the European Food Safety Authority. It remains the only Akkermansia strain to hold that authorization.
-
EFSA Novel Food Authorization
-
GRAS Notification (US)
Patented
Pasteurization Process
20+ Years
of Continuous Research
